TITLE

At the BioCrossroads

AUTHOR(S)
Hromadka, Erik
PUB. DATE
September 2007
SOURCE
Indiana Business Magazine;Sep2007, Vol. 51 Issue 9, p19
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article focuses on BioCrossroads, which makes Indiana one of the nation's top leaders in life science sector. It states that the company is focusing on leveraging the state's assets to create new business opportunities in the sector. According to David Johnson, president and chief executive officer (CEO) of Bio, the company plans to collaborate with its San Diego counterparts to find synergy in biotechnology development and pharmaceuticals.
ACCESSION #
26801262

 

Related Articles

  • Baker & Daniels partner to lead BioCrossroads. Adams, Brent // Indianapolis Business Journal;12/26/2004, Vol. 25 Issue 42, p27 

    Reports that Baker and Daniels partner David Johnson was named president and CEO of BioCrossroads, the life sciences initiative of Indiana. Replacement of Charles Schalliol; Career highlights; Strengths of the BioCrossroads program; Johnson's representation of many of the region's life sciences...

  • Luring people with bricks, mortar. Harton, Tom // Indianapolis Business Journal;10/10/2005, Vol. 26 Issue 31, p12 

    Comments on the construction designs of garage proposals in Indiana. Effects of architectural designs of buildings on people and on the business; Importance of well-designed buildings by David Johnson, president and CEO of the BioCrossroads Co. economic development initiative; Suggestions on...

  • BioCrossroads: It can happen here. Wall, J. K. // Indianapolis Business Journal;2/4/2008, Vol. 28 Issue 49, p1A 

    The article reports on BioCrossroads' issuance of a report that attempts to show in detail the vast market opportunity they see in the drug industry. The report was written by the company three months after launching an initiative to boost drug-development firms in Indiana. BioCrossroads' report...

  • Life Sciences Initiative renamed BioCrossroads. Maurer, Katie; Olson, Scott // Indianapolis Business Journal;10/20/2003, Vol. 24 Issue 32, p47 

    Announces the name change of the biotechnology company Central Indiana Life Science Initiative to BioCrossroads.

  • BioCrossroads aims to aid sciences service sector. Schnitzler, Peter // Indianapolis Business Journal;11/20/2006, Vol. 27 Issue 37, p5 

    The article reports on the capital formation effort of BioCrossroads, the life sciences initiative in Indiana. BioCrossroads Chief Executive Officer David Johnson explained the focus on biotech services businesses. The initiative may form an informal network of angel investors, similar to the...

  • FAITH, SCIENCE & BUSINESS. Wall, J. K. // Indianapolis Business Journal;11/5/2012, Vol. 33 Issue 36, p17A 

    An interview with BioCrossroads chief executive officer (CEO) David Johnson is presented. He explains why he thinks that science and faith are not conflicting concepts. He discusses the role played by faith in his life after he lost in the 2000 U.S. Senate election to Dick Lugar. Moreover, he...

  • Ex-Lilly execs take on diabetes. Schnitzler, Peter // Indianapolis Business Journal;11/6/2006, Vol. 27 Issue 35, p1A 

    The article announces that four former top scientists at Eli Lilly and Co. have formed Carmel, Indiana-based company BioCrossroad to develop diabetes therapies. Industry observers cites the potential success of BioCrosscroad under chief executive officer David Johnson and chairman Gus Watanabe,...

  • Not-for-profit to link to biopharma research. Heikens, Norm // Indianapolis Business Journal;11/5/2007, Vol. 28 Issue 35, p35 

    The article reports that BioCrossroads has established the non-profit organization, BioCrossroadsLinx. The organization will find ways to link pharmaceutical research in San Diego, California and other biotechnology centers to Indiana companies and universities that can turn discoveries into...

  • Twilight rejected by Future Fund. Schnitzler, Peter // Indianapolis Business Journal;4/5/2004, Vol. 25 Issue 4, p1 

    Reports that Indiana-based biotechnology venture capital firm Twilight Ventures LLC has been found ineligible for any share of the Indiana Future Fund that BioCrossroads raised in the fall of 2003 for local biotechnology entrepreneurship. Twilight's concern that most of the money will end up...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics